TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases

Journal of Receptors and Signal Transduction

Volumn 25, Issue 4-6, 2005, Pages 217-235

  Szokolóczi, Orsolya ^a   Schwab, Richárd ^a   Peták, István ^a   Örfi, László ^a   Pap, Ákos ^a   Eberle, Alex N ^b   Szüts, Tamás ^c   Kéri, György ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c Biostatin Research and Development Ltd   (Hungary)

Author keywords

Analogue; Anti inflammatory; Apoptosis; Clinical trial; Neurogenic inflammation; Signal transduction inhibitor; Somatostatin; TT232

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLCYSTEINYLTHREONINAMIDE 2,6 DISULFIDE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 4;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFLAMMATORY DISEASE; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEOPLASMS; PEPTIDES, CYCLIC; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION;

EID: 30344440802     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890500464621     Document Type: Review

References (62)

1. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review. Digestion 2000, 62(Suppl 1), 84-91.
2. Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003, 18, 375-386.
3. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: A critical review. Curr Protein Pept Sci 2003, 4, 339-356.
4. Berthet B, Guillou N, Brioche MI, Choux R, Viret P, Ledoray V, Billardon M, Assadourian R. Influence of somatostatin on acute pancreatitis in rats. Eur J Surg 1998, 164, 785-790.
5. Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000, 135, 112-121.
6. Keri G, Mezo I, Horvath A, Vadasz Z, Teplan I, Balogh A, Csuka O, Bokonyi G, Szoke B, Horvath J, Idei M, Seprodi J. Tumor growth-inhibiting somatostatin analogues, pharmaceutical compositions containing them and process for preparing same. CA2060034 1992, July 26.
7. Keri G, Erchegyi J, Horvath A, Mezo I, Idei M, Vantus T, Balogh A, Vadasz Z, Bokonyi G, Seprodi J, Teplan I, Csuka O, Tejeda M, Gaal D, Szegedi Z, Szende B, Roze C, Kalthoff H, Ullrich A. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci USA 1996, 93, 12513-12518.
8. Vantus T, Csermely P, Teplan I, Keri G. The tumor-selective somatostatin analog, TT2-32 induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620. Tumour Biol 1995, 16, 261-267.
9. Vantus T, Keri G, Krivickiene Z, Valius M, Stetak A, Keppens S, Csermely P, Bauer PI, Bokonyi G, Declercq W, Vandenabeele P, Merlevede W, Vandenheede JR. The somatostatin analogue TT-232 induces apoptosis in A431 cells: Sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases. Cell Signal 2001, 13, 717-725.
10. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 1999, 13, 24-37.
11. Stetak A, Lankenau A, Vantus T, Csermely P, Ullrich A, Keri G. The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src. Biochem Biophys Res Commun 2001, 285, 483-488.
12. Stetak A, Csermely P, Ullrich A, Keri G. Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta. Biochem Biophys Res Commun 2001, 288, 564-572.
13. Lee JU, Hosotani R, Wada M, Doi R, Koshiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Hirohashi M, Uehara T, Arano Y, Fujii N, Imamura M. Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells. Eur J Cancer 2002, 38, 1526-1534.
14. Szegedi Z, Takacs J, Szende B, Vadasz Z, Horvath A, Gulyas E, Toth G, Petak I, Bocsi J, Keri G. A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells. Endocrine 1999, 10, 25-34.
15. Tovari J, Szende B, Bocsi J, Falaschi A, Simoncsits A, Pongor S, Erchegyi J, Stetak A, Keri G. A somatostatin analogue induces translocation of Ku 86 autoantigen from the cytosol to the nucleus in colon tumour cells. Cell Signal 1998, 10, 277-282.
16. Tsutsumi H, Tani K, Fujii H, Miwa S. Expression of L- and M-type pyruvate kinase in human tissues. Genomics 1988, 2, 86-89.
17. Guminska M, Stachurska MB, Ignacak J. Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour, Morris hepatoma 7777 and normal mouse and rat livers. Biochim Biophys Acta 1988, 966, 207-213.
18. Mellati AA, Yucel M, Altinors N, Gunduz U. Regulation of M2-type pyruvate kinase from human meningioma by allosteric effectors fructose 1,6 diphosphate and L-alanine. Cancer Biochem Biophys 1992, 13, 33-41.
19. Tani K, Yoshida MC, Satoh H, Mitamura K, Noguchi T, Tanaka T, Fujii H, Miwa S. Human M2-type pyruvate kinase: cDNA cloning, chromosomal assignment and expression in hepatoma. Gene 1988, 73, 509-516.
20. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003, 23, 1149-1154.
21. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: A crossroad in the tumor metabolome. Br J Nutr 2002, 87 (Suppl 1), S23-S29.
22. Diaconu CC, Szathmari M, Keri G, Venetianer A. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 1999, 80, 1197-1203.
23. Siegrist W, Stutz S, Eberle AN. Homologous and heterologous regulation of alpha-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res 1994, 54, 2604-2610.
24. Siegrist W, Solca F, Stutz S, Giuffre L, Carrel S, Girard J, Eberle AN. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989, 49, 6352-6358.
25. Schwab RE, Froidevaux S, Paku S, Tejeda M, Szende B, Pap A, Beglinger C, Eberle AN, Keri G. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours. Anticancer Res 2001, 21, 71-75.
26. Keri G, Mezo I, Horvath A, Vadasz Z, Balogh A, Idei M, Vantus T, Teplan I, Mak M, Horvath J, et al. Novel somatostatin analogs with tyrosine kinase inhibitory and antitumor activity. Biochem Biophys Res Commun 1993, 191, 681-687.
27. Szende B, Horvath A, Bokonyi G, Keri G. Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. Br J Cancer 2003, 88, 132-136.
28. Tejeda M, Gaal D, Barna K, Csuka O, Keri G. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts. Anticancer Res 2003, 23, 4061-4066.
29. Tejeda M, Gaal D, Schwab RE, Pap A, Szuts T, Keri G. Influence of various administration routes on the antitumor efficacy ofTT-232, a novel somatostatin analog. Anticancer Res 2000, 20, 1023-1027.
30. Szolcsanyi J, Pinter E, Helyes Z, Oroszi G, Nemeth J. Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Br J Pharmacol 1998, 125, 916-922.
31. Szolcsanyi J. Neurogenic inflammation: Reevaluation of axon reflex theory. In: Gepetti G, Holzer P, Ed. Neurogenic Inflammation, Boca Raton, Florida, CRC Press, 1996, 33-42.
32. Selmer I, Schindler M, Allen JP, Humphrey PP, Emson PC. Advances in understanding neuronal somatostatin receptors. Regul Pept 2000, 90, 1-18.
33. ten Bokum AM, Hofland LJ, van Hagen PM. Somatostatin and somatostatin receptors in the immune system: A review. Eur Cytokine Netw 2000, 11, 161-176.
34. Weinstock JV. Production of neuropeptides by inflammatory cells within the granulomas of murine schistosomiasis mansoni. Eur J Clin Invest 1991, 21, 145-153.
35. Vanhagen PM, Markusse HM, Lamberts SW, Kwekkeboom DJ, Reubi JC, Krenning EP. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 1994, 37, 1521-1527.
36. Reubi JC, Mazzucchelli L, Laissue JA. Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 1994, 106, 951-959.
37. Reubi JC, Waser B, Markusse HM, Krenning EP, VanHagen M, Laissue JA. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 1994, 271, 371-378.
38. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989, 264, 949-952.
39. van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW. Somatostatin and the immune and haematopoetic system: A review. Eur J Clin Invest 1994, 24, 91-99.
40. Lembeck F, Donnerer J, Bartho L. Inhibition of neurogenic vasodilation and plasma extravasation by substance P antagonists, somatostatin and [D-Met2, Pro5] enkephalinamide. Eur J Pharmacol 1982, 85, 171-176.
41. Sicuteri F, Raino L, Geppetti P. Substance P and endogenous opioids: How and where they could play a role in cluster headache. Cephalalgia 1983, 3 (Suppl 1), 143-145.
42. Misery L. Skin, immunity and the nervous system. Br J Dermatol 1997, 137, 843-850.
43. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999, 29, 2454-2463.
44. Muscettola M, Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon gamma production by human peripheral blood mononuclear cells. Immunobiology 1990, 180, 419-430.
45. Scicchitano R, Dazin P, Bienenstock J, Payan DG, Stanisz AM. The murine IgA-secreting plasmacytoma MOPC-315 expresses somatostatin receptors. J Immunol 1988, 141, 937-941.
46. Blum AM, Metwali A, Mathew RC, Elliott D, Weinstock JV. Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni. J Immunol 1993, 151, 6994-7004.
47. Eglezos A, Andrews PV, Helme RD. In vivo inhibition of the rat primary antibody response to antigenic stimulation by somatostatin. Immunol Cell Biol 1993, 71(Pt 2), 125-129.
48. Berman AS, Chancellor-Freeland C, Zhu G, Black PH. Substance P primes murine peritoneal macrophages for an augmented proinflammatory cytokine response to lipopolysaccharide. Neuroimmunomodulation 1996, 3, 141-149.
49. Niedermuhlbichler M, Wiedermann CJ. Suppression of superoxide release from human monocytes by somatostatin-related peptides. Regul Pept 1992, 41, 39-47.
50. Kolasinski SL, Haines KA, Siegel EL, Cronstein BN, Abramson SB. Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum 1992, 35, 369-375.
51. Wiedermann CJ, Reinisch N, Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 1993, 82, 954-960.
52. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, Levite M. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000, 165, 2955-2961.
53. Gibbons W, Hughes R, Szeto A, Charalambous M, Aulabaugh A, Mascagni P, Toth I. Lipidic peptides I. Synthesis resolution and structural elucidation of fatty amino acids and their homo- and hetero-oligomers. Liebigs Ann Chem 1990, 12, 1175-1183.
54. Toth I. A novel chemical approach to drug delivery: Lipid amino acid conjugates. J Drug Target 1994, 2, 217-239.
55. Toth I, Malkinson JP, Flinn NS, Drouillat B, Horvath A, Erchegyi J, Idei M, Venetianer A, Artursson P, Lazorova L, Szende B, Keri G. Novel lipoamino acid- and liposaccharide-based system for peptide delivery: Application for oral administration of tumor-selective somatostatin analogues. J Med Chem 1999, 42, 4010-4013.
56. Brittain D, Watterson M, Claridge T, Smith M, Fleet G. Tetrahydrofuran amino acids - Versatile building blocks for unnatural biopolymers: Lack of secondary structure in oligomeric carbopeptoids derived from a D-galacto-5-(aminomethyl) tetrahydrofuran2-carboxylic acid. J Chem Soc Perkin Trans 2000, 21, 3655-3665.
57. Lohof E, Burkhart F. In: Abel A, Ed. Advances in Amino Acid Mimetics and Peptidomimetics. Stanford, Conneticut: JAI Press Inc., 1999, 2, 263-292.
58. Suhara Y, Hildreth J, Ichikawa Y. Synthesis of a new carbohydrate mimetics: "Carbopeptoid containing a C-1 carboxylate and C-2 amino group." Tetrahedron Lett 1996, 37, 1575-1578.
59. Wessel H, Mitchell C, Lobato C, Schmid G. Saccaride-peptide hybrids as novel oligisaccharide mimetics. Angew Chem 1995, 34, 2712-2713.
60. Keri G, Szolcsanyi J, Pinter E, Helyes Z, Erchegyi J, Horvath A, Horvath J, Teplan I, Orfi L. Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects. US Patent 6689813 2004, Feb 10.
61. Orfi L, Waczek F, Kövesdi I, Meszaros G, Idei M, Horvath A, Hollosy F, Mak M, Szegedi Z, Szende B, Keri G. New antitumor leads from a peptidomimetic library. Lett Pept Sci 1999, 6, 325-333.
62. Bajor T, Keri G, Oerfi L. Process for producing phenylamino-acetyl- hydrazide derivatives and pharmaceutical compositions containing the said compounds with tumor growth and enzyme activity-inhibiting effect. Patent No HU214061 1998, April 28.